Well funded with safety and toxicity results due anytime as well as updates regarding phase 1 . The additions to the team imo show confidence its going to happen and the stock should re rate . If there delays it is normal , but this is the least risky of the process moving into Phase 1 and remember Phase 1 is a small cohort of patients .
Ann: Key Executive Appointments to Support Clinical Studies, page-11
Add NSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.205M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 214285 | 3.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 75583 | 1 |
View Market Depth
| Last trade - 16.12pm 15/11/2024 (20 minute delay) ? |
| NSB (ASX) Chart |
Day chart unavailable